Drug Trial Radar · NCT05259033
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
683
Actual
Start
Apr 11, 2022
Primary completion
Dec 13, 2023
Study completion Jan 16, 2024
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Feb 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to semaglutide taken once a week in people with type 2 diabetes. The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to semaglutide. Participants will either get IcoSema or semaglutide. Which treatment participants get is decided by chance. IcoSema is a new medicine that doctors cannot prescribe. Doctors can already prescribe semaglutide in many countries. Participants will get IcoSema or semaglutide, which they must inject once a week with a pen, which has a small needle, in a skin fold in the thigh, upper arm, or stomach. The study will last for about 1 year and 1 month. Participants will have 18 clinic visits, 34 phone/video calls with the study doctor, and 4 contacts with the site that can either be clinic visits or phone/video calls. At 11 clinic visits participants will have blood samples taken. At 7 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.
Conditions
- Diabetes Mellitus, Type 2
Interventions
IcoSemaDrug
IcoSema once weekly subcutaneously (s.c., under the skin) using a needle and a pen. For about 1 year and 1 month.
Semaglutide 1 mgDrug
Semaglutide once weekly subcutaneously (s.c., under the skin). Dose titrated to 1mg over 8 weeks (0.25 mg for 4 weeks, 0.5 mg for 4 weeks). For about 1 year and 1 month.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Glycosylated Haemoglobin (HbA1c)Time frame: Baseline (week 0), (week 52)
Locations
193 sites in 15 countries. Site status is shown where the registry gives one.
Univ of AL at Birmingham_BRM
Birmingham, Alabama
Pri Med Grp dba/Gil Ctr Fam
Gilbert, Arizona
Phoenician Centers for Research & Innovation PCRI
Phoenix, Arizona
Clinical Research Institute of Arizona
Sun City West, Arizona
John Muir Physicians Network
Concord, California
Scripps Whittier Diabetes Inst
La Jolla, California
Clinical Trials Research_Sacramento
Lincoln, California
Downtown LA Res Ctr. Inc.
Los Angeles, California
Velocity Clin Res Los Angeles
Los Angeles, California
Velocity Clin Res Wstlke
Los Angeles, California
Valley Clinical Trials, Inc.
Northridge, California
San Diego Family Care_San Diego
San Diego, California
Premier Medical Center, Inc.
Toluca Lake, California
Northeast Research Institute
Fleming Island, Florida
Encore Medical Research LLC
Hollywood, Florida
Northeast Res Inst. Inc.
Jacksonville, Florida
Est Cst Inst for Rsrch,Jksnvil
Jacksonville, Florida
University Of Miami
Miami, Florida
South Broward Research LLC
Miramar, Florida
Adult Medicine of Lake County, Inc.
Mt. Dora, Florida
Clinical Neuroscience Solution
Orlando, Florida
Florida Institute For Clinical Research
Orlando, Florida
Oviedo Medical Research, LLC
Oviedo, Florida
Metabolic Research Institute Inc
West Palm Beach, Florida
Javara/Privia Med Grp GA,LLC
Albany, Georgia
Endo Res Solutions Inc
Roswell, Georgia
East West Med Res Inst
Honolulu, Hawaii
Saltzer Medical Group Research
Nampa, Idaho
Cedar-Crosse Research Center
Chicago, Illinois
Macoupin Research Group
Gillespie, Illinois
Endeavor Health
Skokie, Illinois
Central Illinois Diabetes and Clinical Research
Springfield, Illinois
Velocity Clin. Res Valparaiso
Valparaiso, Indiana
Iowa Diab & Endo Res Center
West Des Moines, Iowa
Cotton-O'Neil Diab & Endo Ctr
Topeka, Kansas
L-MARC Research Center
Louisville, Kentucky
Four Rivers Clinical Research Inc
Paducah, Kentucky
Ileana J Tandron APMC
Slidell, Louisiana
MedStar Hlth Res Institute
Hyattsville, Maryland
ActivMed Practice & Research LLC
Methuen, Massachusetts
Showing 40 of 193 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.